Mainz Biomed N.V. (MYNZ) — SEC Filings
Mainz Biomed N.V. (MYNZ) — 28 SEC filings. Latest: 6-K (Nov 26, 2025). Includes 24 6-K, 2 20-F, 2 SC 13G/A.
View Mainz Biomed N.V. on SEC EDGAR
Overview
Mainz Biomed N.V. (MYNZ) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 6-K filed on Nov 26, 2025: Mainz Biomed N.V. filed a Form 6-K on November 26, 2025, reporting a Deed of Amendment executed on November 13, 2025. Key changes include decreasing the nominal value of ordinary and preferred shares from €0.40 to €0.01 and increasing authorized share capital to €125,000, comprising 11,250,000 ordin
Sentiment Summary
Across 28 filings, the sentiment breakdown is: 3 bullish, 1 bearish, 23 neutral, 1 mixed. The dominant filing sentiment for Mainz Biomed N.V. is neutral.
Filing Type Overview
Mainz Biomed N.V. (MYNZ) has filed 24 6-K, 2 20-F, 2 SC 13G/A with the SEC between Feb 2024 to Nov 2025.
Filings by Year
Recent SEC Filings (28)
Risk Profile
Risk Assessment: Of MYNZ's 26 recent filings, 1 were flagged as high-risk, 13 as medium-risk, and 12 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Key Executives
- Guido Baechler
Industry Context
Mainz Biomed N.V. operates in the pharmaceutical preparations industry, focusing on the development and commercialization of diagnostic tests.
Top Tags
corporate-governance (6) · financing (5) · shareholder-meeting (5) · securities-offering (3) · warrants (3) · compliance (3) · press-release (3) · corporate-action (2) · capital-raise (2) · financial-report (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| New Nominal Share Value | €0.01 | Reduced from €0.40 for ordinary and preferred shares. |
| Authorized Share Capital | €125,000 | Increased to this amount. |
| Aggregate Offering Amount | $10.0M | Maximum amount of ordinary shares Mainz Biomed can sell through the Sales Agent. |
| Pre-funded Units Sold | 2,222,222 | Represents the volume of securities transacted in the offering. |
| Ordinary Units Sold | 375,000 | Represents the quantity of units, each containing a share and warrants, sold to an institutional investor. |
| Fiscal Year End | 2024 | The report covers the company's performance up to this date. |
| Filing Date | 20250331 | This is the date the annual report was submitted to the SEC. |
| Minimum Stockholders' Equity | $2.5 million | Requirement for continued listing on Nasdaq Capital Market that Mainz Biomed no longer meets. |
| Follow-on Offering | $8.0M | Capital raised by Mainz Biomed |
| Year Agreement | 2 | Duration of the research collaboration |
| Conversion Price | $3.5424 | One of the potential conversion prices for the promissory note into ordinary shares. |
| Total Promissory Notes | $11.0B | Represents the aggregate principal amount of the two notes issued to Yorkville. |
| Individual Note Amount | $5.5B | The principal amount for each of the two promissory notes issued. |
| Outstanding Ordinary Shares | 21,165,482 | As of December 31, 2023 |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Mainz Biomed N.V. (MYNZ)?
Mainz Biomed N.V. has 28 recent SEC filings from Feb 2024 to Nov 2025, including 24 6-K, 2 20-F, 2 SC 13G/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of MYNZ filings?
Across 28 filings, the sentiment breakdown is: 3 bullish, 1 bearish, 23 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Mainz Biomed N.V. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Mainz Biomed N.V. (MYNZ) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Mainz Biomed N.V.?
Financial highlights for Mainz Biomed N.V. are available when 10-K or 10-Q filings are enriched with AI analysis. Check back as new filings are processed.
What is the investment thesis for MYNZ?
The investment thesis for MYNZ includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Mainz Biomed N.V.?
Key executives identified across Mainz Biomed N.V.'s filings include Guido Baechler.
What are the main risk factors for Mainz Biomed N.V. stock?
Of MYNZ's 26 assessed filings, 1 were flagged high-risk, 13 medium-risk, and 12 low-risk.
What are recent predictions and forward guidance from Mainz Biomed N.V.?
Forward guidance and predictions for Mainz Biomed N.V. are extracted from SEC filings as they are enriched.